Genome-wide studies have shown that allelic variations in the melatonin receptor 2 (MT2) contribute to the elevations in fasting glucose levels in plasma, insulin resistance, and ultimately the risk for type 2 diabetes [142, 143]. The gene discussed is MTNR1B; the disease is type 2 diabetes mellitus.